tbuckley/cabot-search huggingface dataset:
Lack of Regional Variation in IDDM Risk in Japan
Journal: Diabetes Care (1993)

OBJECTIVE To examine the intracountry variation of IDDM incidence in Japan and compare it with data from the British Isles and the U.S. RESEARCH DESIGN AND METHODS IDDM incidence was determined with a standardized registry approach in five geographically different areas in Japan (Hokkaido, Tokyo, Yokohama, Osaka, and Kagoshima) with a total at-risk population &amp;lt; 15 yr of age of 4.4 million. Data collection was completed under the guidelines of the World Health Organization Diamond project. RESULTS The incidence and patterns of disease were remarkably similar across the five environmentally different areas. Incidence rates per 100,000 were very low and almost identical from northern to southern Japan (Hokkaido, 2.07; Tokyo, 1.65; Yokohama, 1.66; Osaka, 1.78; and Kagoshima, 1.93). This remarkably low intracountry variation of 0.4/100,000 stands in sharp contrast with the 13.0/100,000 regional variation in the British Isles and the 10.6/100,000 variation in the U.S. CONCLUSIONS The results suggest that the remarkable genetic homogeneity in Japan may produce uniformity of incidence.
Pancreatic pseudocyst in the left hepatic lobe: A report of two cases
Authors: K Okuda
Journal: Hepatology (1991)

The ultrasound and computed tomographic imaging features in a rare pancreatic pseudocyst of the liver are described in two patients. The pseudocysts occurred in the left lobe in both cases, one after a traumatic injury and the other after alcoholic pancreatitis. The possible topographical sequences with which pancreatic secretions entered the left hepatic lobe to form a cyst are discussed. (HEPATOLOGY 1991;13:359–363).
Weight Loss in Breast Cancer Patient Management
Authors: R. T. Chlebowski
Journal: Journal of Clinical Oncology (2002)

PURPOSE: To systematically review and summarize evidence relevant to obesity and breast cancer clinical outcome, potential hormonal mediating mechanisms, and the current status of weight loss interventions for chronic disease management. METHODS: A comprehensive, formal literature review was conducted to identify 5,687 citations with key information from 159 references summarized in text and tables. This process included a search for all breast cancer studies exploring associations among survival or recurrence and obesity at diagnosis or weight gain after diagnosis using prospective criteria. RESULTS: On the basis of observational studies, women with breast cancer who are overweight or gain weight after diagnosis are found to be at greater risk for breast cancer recurrence and death compared with lighter women. Obesity is also associated with hormonal profiles likely to stimulate breast cancer growth. Recently, use of weight loss algorithms proven successful in other clinical settings that incorporate dietary therapy, physical activity, and ongoing behavior therapy have been endorsed by the National Institutes of Health and other health agencies. CONCLUSION: Although definitive weight loss intervention trials in breast cancer patients remain to be conducted, the current evidence relating increased body weight to adverse breast cancer outcome and the documented favorable effects of weight loss on clinical outcome in other comorbid conditions support consideration of programs for weight loss in breast cancer patients. Recommendations for the clinical care of overweight or obese breast cancer patients are offered.
Breast cancer hotline to resume operation
Authors: G. McBride
Journal: JAMA (1981)

For women with breast cancer who are confused about their treatment options, there is help on an authoritative lay level. Rose Kushner, a former breast cancer patient and a lay member of the President's National Cancer Advisory Board, will resume her telephone hotline for breast cancer patients on March 15. The new phone number of Kushner's Breast Cancer Advisory Service is not yet known, but the new offices of the service will be located at 7910 Woodmont Ave, Bethesda, MD 20014, very close to the National Cancer Institute (NCI). The one woman-plus-volunteers service has been in existence for more than four years and has handled 12,000 or so written and telephone inquiries during that time. But it has been located in Kushner's home and, partly because Kushner finds it difficult to refuse to help a worried woman in search of information, it got to be too disruptive for her and
PWE-236 White cell aphaeresis (WCA) with adacolumn is effective in selected cases of chronic refractory colitis with high histological activity
Authors: P Premchand, L Ford, D Venkama
Journal: Gut (2012)

<h3>Introduction</h3> Treatment options for patients with chronic refractory colitis are limited. White cell aphaeresis (WCA) is effective in inducing clinical remission in chronic refractory colitis in patients with a strong inflammatory burden at baseline and histologically active disease. Previous multinational sham controlled trials have demonstrated significant improvement when patients with high histological activity (modified Rileys score) are selected for treatment. <h3>Methods</h3> A prospective study was conducted in 30 patients with severe steroid -dependent or steroid -refractory ulcerative colitis referred for WCA. Inclusion criteria were (i) High disease activity score (partial Mayo score ≥6) (ii) Intractable symptoms despite treatment with steroids and/or immunosuppressants (iii) Severe disease at endoscopy and histologically. The aim was to induce clinical and IBD-Q remission at 12 weeks. A Mayo score ≤3 defined clinical remission. The 32 item Inflammatory Bowel Disease questionnaire (IBD-Q) was used to assess quality of life prior to treatment and at 12 weeks. <h3>Results</h3> <b>Patient Characteristics</b>: Prior to treatment 28 patients (93.3%) were prescribed 5-ASA compounds. 12 patients (40%) were prescribed topical therapies (5-ASA enemas or suppositories/steroids enemas). 27 patients (90%) were steroid dependent (Prednisolone mean dose 21.1 mg, median 20 mg). Three patients (10%) were steroid refractory (no response to high dose oral steroids). 13 patients (43.3%) were prescribed Azathioprine of the remainder all had documented intolerance or a contraindication. One patient (3.3%) was prescribed six Mercaptopurine. Five patients had failed Infliximab (16.6%) and in one patient (3.3%) it was contraindicated. 1 patient (3.3%) had failed intramuscular Methotrexate. <b>Outcomes</b>: At week 12 clinical remission (Mayo score ≤3) was achieved in 22 patients (73.3%), 18 patients (60%) were no longer prescribed oral steroids. IBD-Q remission at week 12 was achieved in 19 patients (63.3%). Of the remainder, five patients (16.6%) achieved an IBD-Q response. Of eight patients (26.6%) who failed to achieve clinical remission at 12 weeks, one achieved delayed remission at 20 weeks. Of the remaining seven treatment failures, five underwent colectomy (16.6%). <h3>Conclusion</h3> WCA can be effective in inducing clinical remission and improving quality of life (IBD-Q) indices in chronic severe steroid refractory ulcerative colitis with highly active disease histologically. This data series suggests WCA should be considered before colectomy in this challenging patient group. <h3>Competing interests</h3> None declared.
The Environment
Authors: George W. Irving
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
24P Establishment of patient-derived xenografts from malignant pleural effusion using NOG mice
Authors: T. Chijiwa, M. Haraguchi, T. Isagawa, A. Noguchi, M. Katayama, N. Miyao, M. Yoshioka, N. Matsui, Y. Tateishi, H. Suemizu, R. Yamada, Y. Nakamura, K. Imai, D. Komura, H. Katoh, S. Ishikawa, M. Nakamura, Y. Miyagi
Journal: Annals of Oncology (2016)
DIPG-08. PHASE IB IMMUNOTHERAPY CLINICAL TRIAL WITH THE USE OF AUTOLOGOUS DENDRITIC CELLS PULSED WITH AN ALLOGENIC TUMORAL CELL LINES LYSATE IN PATIENTS WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG)
Authors: Andres Morales La Madrid, Manel Juan, Dani Benitez, Ofelia Cruz, Jaume Mora, Angel M Carcaboso, Azucena Gonzalez, Carolina España, Raquel Cabezon, Sonia Paco
Journal: Neuro-Oncology (2017)

Diffuse intrinsic pontine glioma (DIPG) is the most frequent brainstem tumor in children. DIPG is well characterized clinically, radiologically and more recently by specific molecular markers. Currently, there is no curative treatment for patients with DIPG. Focal irradiation is the only treatment that stops tumor progression-in most of patients- for a few months. However, the majority of patients with DIPG succumb to their disease during the first 2 years after diagnosis. Thus, novel and more efficacious therapeutic interventions are desperately needed. This Ib pilot study explores the use of immunotherapy with dendritic cells (DC) for the treatment of patients with newly diagnosed DIPG. In short, patient´s DC are extracted at diagnosis or after irradiation completion by leukapheresis and are primed with a tumoral lysate composed of 8 cell lines obtained from 5 patients with molecularly proved DIPG. This tumoral lysate offers a wide range of tumoral antigens specific for DIPG cells which will generate specific and non-specific antitumoral response when exposed to DC. The principal goal of this pilot study is to establish the feasibility and safety of the intradermic administration of DC vaccines in patients with DIPG after radiation therapy. Also, we will evaluate the non-specific and antitumoral immune response generated in serum/CSF, and if this response translates into clinical and/or radiologic response. Additionally, we will study if there is correlation between the immune response generated and improved overall survival for this cohort of patients. This pilot study is designed to include 10 patients. To date, 2 patients have been included and receiving therapy with no toxicity identified. Three more patients will be included within the next few weeks. We expect to have some of the data mentioned above by June 2017. We believe it is important to share these data with the pediatric neuro-oncology scientific community.
Immunohematologic Diseases
Authors: Burton Zweiman
Journal: JAMA (1982)

<h3>IMMUNE DISEASES INVOLVING RBCs</h3> NEARLY 400 different blood group antigens have been identified on the red cell membrane by their corresponding antibodies. As a result of this heterogeneity, the antigenic makeup of each individual's red cell is unique. Fortunately, most of these antigens are not highly immunogenic, otherwise blood transfusion would be impossible. For practical purposes, only the antigens of the ABO system and the D antigen in the Rh system are matched routinely. <h3>ABO Blood Group System</h3> Landsteiner published his discovery of the ABO blood group system in 1901; he had noted that serum from some of his laboratory employees would agglutinate red cells of other laboratory workers. Later, people were assigned to four categories that became known as the A, B, 0, and AB blood groups (Table 10-1). By about 6 months of age, normal persons form antibodies against the antigens of the ABO system that they lack.
FAST GLYCOSYLATION OF HÆMOGLOBIN
Authors: P.Aaby Svendsen, J.Sandahl Christiansen, A.Renard Andersen, B Welinder, J Nerup, Geremia Bolli, MariaG Cartechini, Pietro Compagnucci, Massimo Massi-Benedetti, Fausto Santeusanio, Paolo Brunetti
Journal: The Lancet (1979)
Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC)
Authors: G. Koutsodontis, G. Papaxoinis, I. Kotsantis, P. Economopoulou, A. Strati, C. Avgerinou, N. Spathas, E. Kirodimos, O. Tsavaris, E. Maratou, L. Hoxhallari, M. Anastasiou, M. Prevezanou, E. Lianidou, A. Psyrri
Journal: Annals of Oncology (2018)
Autoimmune Pancreatitis
Authors: Eva Fjordside, Srdan Novovic, Palle Nordblad Schmidt, Ida Vind, Erik Feldager Hansen
Journal: New England Journal of Medicine (2007)

Autoimmune pancreatitis (AIP) is a rare inflammatory disease. AIP has characteristic histology, serology and imaging findings. Two types of AIP exist, type 1, which is a part of the systemic immunoglobulin G4-related disease, and type 2, which is only localized to the pancreas. Patients with type 1 are predominantly older men, have involvement of other organs and more often experience relapse than patients with type 2. Both types respond well to steroid treatment. The most important differential diagnose is pancreatic cancer.
The Expression of E-Cadherin in Somatotroph Pituitary Adenomas Is Related to Tumor Size, Invasiveness, and Somatostatin Analog Response
Authors: Stine Lyngvi Fougner, Tove Lekva, Olivera Casar Borota, John K. Hald, Jens Bollerslev, Jens Petter Berg
Journal: Endocrine Reviews (2010)
Increased lysophosphatidylcholine and pancreatic enzyme content in bile of patients with anomalous pancreaticobiliary ductal junction
Authors: K Shimada
Journal: Hepatology (1991)

A high incidence of inflammation and carcinoma of the biliary tract in patients with anomalous pancreaticobiliary ductal junction has been well documented. The change in biliary phospholipids as a result of the reflux of pancreatic juice into the biliary tract through anomalous pancreaticobiliary ductal junction may be responsible for it. We developed a new method of analysis of phospholipid classes using aminopropyl Bond Elut cartridge for extraction and highperformance liquid chromatography for separation. Satisfactory recovery was achieved (i.e., more than 95% for both phosphatidylcholine and lysophosphatidylcholine). With this method, the bile of 11 patients with anomalous pancreaticobiliary ductal junction was examined. The concentration and proportion of lysophosphatidylcholine in bile were much higher in the presence of anomalous pancreaticobiliary ductal junction than in controls (3.44 ± 1.50 mmol/L vs. 0.52 ± 0.25 mmol/L, 60.0% ± 31.0% vs. 2.3% ± 1.4% in gallbladder bile; p <0.001). In contrast, the concentration of phosphatidylcholine and the sum of phosphatidylcholine and lysophosphatidylcholine in gallbladder bile significantly decreased (p <0.001), but in hepatic bile they did not. An inverse correlation was found between the proportion of lysophosphatidylcholine and phospholipid concentration in gallbladder bile. Phospholipase A2 and amylase activities in bile were markedly high. Increased total fatty acid concentration and proportion of unsaturated fatty acid in bile were found. Total bile acid concentration in gallbladder bile was significantly lower than in controls. These results suggest that a considerable amount of lysophosphatidylcholine, which is known to have a cytotoxic effect, is produced by phospholipase A2 in refluxing pancreatic juice, and an increased concentration of lysophosphatidylcholine gives rise to cell damage causing mucosal hyperplasia and metaplasia. This condition may be one of the factors responsible for the occurrence of carcinoma of the biliary tract. (HEPATOLOGY 1991;13:s438–444.)
Stereophonic auscultation.
Authors: B L Dalton
Journal: BMJ (1972)

the dose we prescribed facilitate further rehabilitation of the patients.Our experience, however, does confinn the findings of other workers that very large doses of the drug do not produce any parallel increase in iatrogenic Parkinsonian symptoms.We felt reluctant to inject the drug more frequently than once a week.The advantage of a longacting parenteral phenothiazine drug lies in its infrequent administration.Daily injection at the dose suggested by Kline et al. negates any advantage that parenteral therapy may have over oral phenothiazines.-Weare, etc.,
A rational next step in the treatment of some rectal adenocarcinomas.
Authors: G Steele, J M Hamilton, J P Karr
Journal: Journal of Clinical Oncology (1989)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1989.7.8.988 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 2754452 A rational next step in the treatment of some rectal adenocarcinomas. G Steele JrxG Steele JrSearch for articles by this author , J M HamiltonxJ M HamiltonSearch for articles by this author , J P KarrxJ P KarrSearch for articles by this author Show More New England Deaconess Hospital Boston. https://doi.org/10.1200/JCO.1989.7.8.988 First Page PDF © 1989 by American Society of Clinical Oncology
Heparin as an antithrombotic agent. Low-dose prophylaxis
Authors: S. Wessler
Journal: JAMA (1976)

PULMONARY embolism is a ubiquitous and frequently lethal complication (50,000 deaths annually<sup>1</sup>of a broad spectrum of medical and surgical diseases and of sedentary living). This mortality is predominantly a hospital-based phenomenon. The hazard to a productive life has been masked by a lack of awareness of the true incidence of pulmonary embolism and by the fact that it is not itself a disease, but rather a complication of a host of major pathologic states. Recent data have documented not only its remarkable scope, its increasing prevalence in our society, but, most importantly, have provided new methods of prophylaxis that are available for general use by physicians and surgeons. In short, venous thromboembolism is on its way to becoming a largely preventable complication of disease. Anticoagulants, particularly heparin sodium in classical doses and the coumarin compounds, are the mainstay of the antithrombotic methods in the prophylaxis of venous thromboembolism.
CANCER OF THE LARGE BOWEL
Authors: J. H. T.
Journal: JAMA (1960)

Those of us who may have assumed that cancer of the large bowel has been conquered would do well to re-examine our clinical experience in the light of several challenging concepts reported elsewhere inThe Journal, p. 1783 and p. 1789. While traditional, ever increasing optimism regarding results of therapy has focused our attention on "ideal" or favorable cases, Gilbertsen candidly calls our attention to the fact that the prognosis for the majority of patients suffering from cancer of the large bowel is unfavorable and that the "average patient" with a malignant lesion of the lower tract will not be cured with present day therapy. He discusses a number of factors related to possible reasons for the present situation and suggests several avenues for improvement. A few readers may be shocked, and some even a bit upset, by the admittedly dramatic manner of presentation. It should be noted that, while
Rubella Vaccination during Pregnancy —United States, 1971-1988
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Gheel revisited
Authors: C. D. Aring
Journal: JAMA (1974)

... —even I Regained my freedom with a sigh. —<i>The Prisoner of Chillon</i> LORD Byron, keen observer of the social scene, whose humor generally was kept in good repair, averred that it would have made little difference early in the nineteenth century if those in institutions for the insane were out, and those out, in. His point is well taken. The most recent move to release long-term mental patients from state hospitals was heralded in 1958, when Dr. Harry Solomon, then President of the American Psychiatric Association, said: I do not see how any reasonably objective view of our mental hospitals today can fail to conclude that they are bankrupt beyond remedy. I believe, therefore, that our large mental hospitals should be liquidated as rapidly as can be done in an orderly and progressive fashion. The mental hospitals in some of the larger states have implemented programs for the phasing
A STUDY OF COMMERCIAL VITAMIN PREPARATIONS
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fatal outcome of methemoglobinemia in an infant
Authors: C. J. Johnson
Journal: JAMA (1987)

CASES of methemoglobinemia in infants and older members of farm families are probably more common than we realize. A 1950 report lists 144 cases of infant methemoglobinemia with 14 deaths in one 30-month period alone in Minnesota.<sup>1</sup>In a 1982 survey of 353 physicians in the ten-county Big Sioux region in eastern South Dakota, 29 physicians reported having treated about 80 cases of methemoglobinemia, of which 64 had occurred more than ten years earlier.<sup>2</sup>All but one case occurred in infants. This preventable, treatable intoxication continues to contribute to infant mortality today. <h3>Report of a Case</h3> A female infant born on April 30, 1986, was breast-fed at first and later received supplementary feedings with a powdered formula mixed with well water. The mother took her to the family physician for a one-month checkup on May 30. At that time, she looked quite healthy, although the mother reported blueness